Role of plants in anticancer drug discovery

被引:120
作者
Khazir, Jabeena [1 ]
Mir, Bilal Ahmad [2 ]
Pilcher, Lynne [1 ]
Riley, Darren L. [1 ]
机构
[1] Univ Pretoria, Dept Chem, ZA-0028 Pretoria, South Africa
[2] Univ Pretoria, Dept Genet, Ctr Microbial Ecol & Genom, ZA-0028 Pretoria, South Africa
关键词
Cancer; Drugs; Natural products; Plant derived anticancer drugs; EVERY; 3; WEEKS; PHASE-I; BETULINIC ACID; NATURAL-PRODUCTS; CANCER CHEMOPREVENTION; INTRAVENOUS-INFUSION; CLINICAL-EXPERIENCE; INDUCED APOPTOSIS; PERILLYL ALCOHOL; STRUCTURAL BASIS;
D O I
10.1016/j.phytol.2013.11.010
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Cancer is one of the major causes of death and the number of new cases, as well as the number of individuals living with cancer, is expanding continuously. Worldwide the alarming rise in mortality rate due to cancer has fuelled the pursuit for effective anticancer agents to combat this disease. Finding novel and efficient compounds of natural origin has been a major point of concern for research in the pharmaceutical sciences. Plants have been seen to possess the potential to be excellent lead structures and to serve as a basis of promising therapeutic agents for cancer treatment. Many successful anti-cancer drugs currently in use or their analogues are plant derived and many more are under clinical trials. This review aims to highlight the invaluable role that plants have played, and continue to play, in the discovery of anticancer agents. (C) 2013 Phytochemical Society of Europe. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:173 / 181
页数:9
相关论文
共 127 条
  • [1] A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer
    Ajani, JA
    Takimoto, C
    Becerra, CR
    Silva, A
    Baez, L
    Cohn, A
    Major, P
    Kamida, M
    Feit, K
    De Jager, R
    [J]. INVESTIGATIONAL NEW DRUGS, 2005, 23 (05) : 479 - 484
  • [2] Akram M., 2010, ROM J BIOL PLANT BIO, V55, P65
  • [3] Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
    Anthoney, D. Alan
    Naik, Jay
    MacPherson, Iain R. J.
    Crawford, Donna
    Hartley, John M.
    Hartley, Janet A.
    Saito, Tomohisa
    Abe, Masaichi
    Jones, Keith
    Miwa, Masanori
    Twelves, Christopher
    Evans, T. R. J.
    [J]. BMC CANCER, 2012, 12
  • [4] ARMSTRONG JG, 1967, CANCER RES, V27, P221
  • [5] Bachner Mark, 2008, Ther Clin Risk Manag, V4, P1243
  • [6] Bao Rudi, 2011, J Exp Pharmacol, V3, P21, DOI 10.2147/JEP.S7804
  • [7] P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain
    Beaulieu, E
    Demeule, M
    Ghitescu, L
    Beliveau, R
    [J]. BIOCHEMICAL JOURNAL, 1997, 326 : 539 - 544
  • [8] Phase II study of ortataxel in taxane-resistant breast cancer
    Beer, M.
    Lenaz, L.
    Amadori, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Vinflunine: A new microtubule inhibitor agent
    Bennouna, Jaafar
    Delord, Jean-Pierre
    Campone, Mario
    Nguyen, Laurent
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (06) : 1625 - 1632
  • [10] Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin
    Bhattacharyya, Bhabatarak
    Panda, Dulal
    Gupta, Suvroma
    Banerjee, Mithu
    [J]. MEDICINAL RESEARCH REVIEWS, 2008, 28 (01) : 155 - 183